Sarepta (SRPT) PT Raised to $47 at Needham & Company; Sees Upside to $60

September 14, 2016 1:54 PM EDT
Get Alerts SRPT Hot Sheet
Price: $33.91 -2.61%

Rating Summary:
    16 Buy, 9 Hold, 1 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 21 | Down: 31 | New: 25
Trade SRPT Now!
Join SI Premium – FREE

Get daily under-the-radar research with's Stealth Growth Insider Get your 2-Wk Free Trial here.

Needham & Company analyst Chad Messer raised his price target on Buy-rated Sarepta Therapeutic (NASDAQ: SRPT) to $47.00 (from $26.00), with upside to $60. Messer said "while we view the departure of FDA reviewer Dr. Ron Farkas as a potential positive for eteplirsen approval, we still believe the requested Western blot data from PROMOVI remains the critical deciding factor."

He added, "As a reminder, Western blot data from the original eteplirsen studies indicated an average increase of dystrophin of ~0.9%, which many FDA and Advisory Committee members found disappointing. However, there were issues with the way the blots were analyzed and a poor correlation between the original and a second analysis. We believe other evidence, such as a demonstration of consistent dystophin mRNA increases, support eteplirsen's mechanism and therefore are inclined to believe the PROMOVI samples will support approval."

They believe approval would justify a $3B+ market cap, or ~$60/share.

For an analyst ratings summary and ratings history on Sarepta Therapeutic click here. For more ratings news on Sarepta Therapeutic click here.

Shares of Sarepta Therapeutic closed at $25.60 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst PT Change, FDA, Hot FDA News

Related Entities

Needham & Company, AdCom

Add Your Comment